Avastin and Lucentis are infact the same drug with Avastin being vastly cheaper and FDA approved for treatment of Colon cancer and Lucentis being the version approved for treatment of wet AMD. Nonethless a lot of opthamlologists have substituted Avastin off label for treating wet AMD to pass on the savings to clients who can't afford Lucentis or Eyelea.
As to why the second trial with Lucentis is taking longer to recruit, my bet is that most patients would have preferred to be in the Eyelea trial because Eyela is generally accepted to be the more potent treatment. However now the first trial is fully recruited you would expect the Lucentis trial to catch up, hopefully by the end of this month.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-38
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
-0.005(1.39%) |
Mkt cap ! $387.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.0¢ | 35.5¢ | $632.4K | 1.766M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 361309 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 38071 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| OPT (ASX) Chart |